Standout Papers

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial 2024 202653
  1. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial (2024)
    Kang Wang, Yan‐Jun Xiang et al. Nature Medicine

Immediate Impact

1 by Nobel laureates 59 standout
Sub-graph 1 of 24

Citing Papers

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Latest advances in hepatocellular carcinoma management and prevention through advanced technologies
2024 Standout
1 intermediate paper

Works of Feiguo Zhou being referenced

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
N‐glycan based models improve diagnostic efficacies in hepatitis B virus‐related hepatocellular carcinoma
2009

Author Peers

Author Last Decade Papers Cites
Feiguo Zhou 181 43 152 263 177 18 558
Wenbing Sun 237 67 124 221 186 25 584
Meng‐Chao Wu 208 36 290 252 133 13 592
Chuan Lin 187 49 87 203 131 16 582
María Elizalde 130 65 104 405 123 17 621
Yih-Jyh Lin 153 97 116 142 98 23 480
Takaaki Imamura 105 31 124 346 180 24 637
Amanda Mikels‐Vigdal 99 89 106 250 169 14 644
Li‐Hwa Wu 151 63 89 186 97 16 524
Jane Birtwistle 111 72 99 207 65 21 540
Yibin Ren 55 52 87 351 160 13 510

All Works

Loading papers...

Rankless by CCL
2026